Thus, pharmacological inhibition of STAT3 activity with fraxetin suppresses the oncogenesis and development of PDA by antagonizing STAT3 activation, and fraxetin can be a therapeutic approach to PDA. This evidence concerns the gene STAT3 and Patent ductus arteriosus.